Minimally Invasive Medical Science Limited (the "Company") announced its 2024 interim report, demonstrating the company's focus on innovation, manufacturing, and selling high-end medical instruments globally. During the reporting period, the company achieved a global revenue of 558.7 million US dollars, a year-on-year growth of 15.8%. However, the company recorded a net loss of 106.674 million US dollars during the same period, with an operating net cash outflow of 33.454 million US dollars. The company faced pressure on liquid assets and implemented various strategies to improve liquidity. The company's net value of liquid assets at the end of the reporting period was 995.263 million US dollars. Additionally, the company completed a private placement of Minimally Invasive Robots in July 2024, and acquired 72.37% equity of OMD in August, making it a wholly-owned subsidiary.

Minimally Invasive Medical Science Limited (the "Company") announced its 2024 interim report, demonstrating the company's focus on innovation, manufacturing, and selling high-end medical instruments globally. During the reporting period, the company achieved a global revenue of 558.7 million US dollars, a year-on-year growth of 15.8%. However, the company recorded a net loss of 106.674 million US dollars during the same period, with an operating net cash outflow of 33.454 million US dollars. The company faced pressure on liquid assets and implemented various strategies to improve liquidity. The company's net value of liquid assets at the end of the reporting period was 995.263 million US dollars. Additionally, the company completed a private placement of Minimally Invasive Robots in July 2024, and acquired 72.37% equity of OMD in August, making it a wholly-owned subsidiary.